Skip To Main Content
Bartomeu Massuti on Muck Rack

Bartomeu Massuti

As seen in: The Lancet, Future Medicine, European Journal of Cancer, Lung Cancer, TechTrends
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Bartomeu

Contact Bartomeu, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05) | Journal of Clinical Oncology

|
By Ernest Nadal, Delvys Rodríguez-Abreu, Marta Simó, Bartomeu Massuti
| brnw.ch
Lung cancer is the most common solid tumor to metastasize to the CNS and about one quarter of patients diagnosed with stage IV non–small-cell lung cancer (NSCLC) have brain metastases at diagnosis.1 Historically, whole-brain radiotherapy (WBRT) had been the cornerstone of treatment for brain metastases in patients with advanced NSCLC, especially when stereotactic radiosurgery (SRS) and surgery were not feasible or indicated.
Open in Who Shared Issue with article?

Phase II Clinical Trial with Metronomic Oral Vinorelbine and Tri-weekly Cisplatin as Induction Therapy, Subsequently Concomitant with Radiotherapy (RT) in Patients with Locally Advanced, Unresectable, Non-Small Cell Lung Cancer (NSCLC). Analysis of Surviv

|
By Mariano Provencio, Margarita Majem, Bartomeu Massuti, María Guirado
| Lung Cancer Verified
Highlights • New drug schemes are needed for unresectable stage III NSCLC • Metronomic chemotherapy based on oral vinorelbine and cisplatin exhibits low toxicity • ctDNA analysis can identify the subgroup of patients who might benefit from this treatment Abstract Background Little progress has been achieved in non-small cell lung cancer (NSCLC) patients with unresectable stage III disease and new drug schemes are warranted.
Open in Who Shared Issue with article?

Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib

|
By Dolores Isla, Bartomeu Massuti, Martín Lázaro, Rocio Gordo
| Future Medicine Verified
Practice points The annual cost derived from the management of advanced ALK+ NSCLC patients with CNS metastases compared with patients without CNS metastases was estimated. An expert panel formed by medical oncologists estimated the healthcare resources consumption of each type of patient (with vs without CNS metastases).
Open in Who Shared Issue with article?
See all 4 articles